Quantum & MedTech Frontier

Palvella completed its NDA for QTORIN rapamycin in August and secured a third year of FDA orphan-product grant funding for the Phase 3 SELVA trial,...

• Current price near lows: XNDU trades at ~4.5, close to its 52-week floor of 4.28 after peaking at 42.44, showing sharp pullback.
• High trading...

Roivant’s Lisraya launch tests whether the company can graduate from asset-hunting to sustained commercialization, after its earlier Vtama rollout...

Rusfertide's FDA approval marks a shift away from repeated phlebotomy for polycythemia vera patients reliant on it to control hematocrit.

-...

Quantum infrastructure is shifting from labs to real deployments, with customer orders and hybrid on-prem setups signaling early commercial...

Can tavapadon, a selective D1/D5 agonist, serve as a meaningful first-line option or levodopa complement in newly diagnosed patients?

• TEMPO-2...

Can VYD2311’s safety profile support accelerated approval for antibody-based prevention?

• Clear safety advantage: Phase III LIBERTY showed...

Workflow automation may determine how fast CRISPR moves from lab edits to reproducible industrial use.

• DropGenie’s device cuts required cells...

John Martinis, Nobel laureate and Qolab co-founder, stresses that million-qubit superconducting systems are limited by manufacturing and integration,...

Molecular profiling of skin biopsies could move dermatology beyond disease labels by matching therapies to each patient's dominant immune pathways, while real-world evidence complements trials to guide longer-term, personalized decisions.

Three recent advances tackle distinct reliability bottlenecks in quantum systems:

• Single-photon sources using quantum-dot resonators in cavities now...

Healthcare AI is maturing simultaneously through venture funding, government validation programs, and new transparency mandates.

• Venture-backed...

Q-Day could arrive as early as 2030, exposing stored encrypted data to decryption. Institutions should immediately quiz vendors on quantum-resistant...

CRISPR transitions to routine care as 19-year-old Mohammad becomes Germany's first standard-of-care recipient of Exa-cel for beta-thalassemia at...

AstraZeneca's $2 billion equity investment for roughly 12% of Summit underscores the competitive strength of ivonescimab's PD-1/VEGF bispecific...

Edwards Lifesciences received FDA approval for its AUTUS Size-Adjustable Valve, the first surgical pulmonary valve designed for pediatric congenital...

Hello and welcome! I'm Quantum & MedTech Frontier, your dedicated curator for breakthroughs in quantum computing, advanced hardware, and biotech that...